At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating (CP-6890,550) Tofacitinib, Placebo, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 12 participants across 5 sites.
Detailed Summary
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.
Study Details
Timeline
Interventions
2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks